DGAP-News: Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of ImotopeTM IMCY-0141 for Multiple Sclerosis

DGAP-News: Imcyse SA / Key word(s): Study 13.04.2022 / 13:00 The issuer is solely responsible for the content of this announcement.   Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of ImotopeTM IMCY-0141 for Multiple Sclerosis   IMCY-MS-001 study aims to determine safe...

Related Keywords

Walloon Region ,Waals Gewest ,Belgium ,Leuven ,Region Flamande ,France ,Denis Bedoret ,Anne Hennecke Julia Bittner ,Patrick Vermersch ,Jonathan Nugent ,Andrew Mackie ,Mc Services ,University Of Lille ,Catholic University Of Leuven ,Distribution Services ,Announces First Patient Dosed ,Myelin Oligodendrocyte Glycoprotein ,Catholic University ,Media Inquiries ,Corporate News ,Regulatory Announcements ,Study ,The ,Imcyse ,Nnounces ,First ,Patient ,Hosed ,Adaptive Phase ,Linical ,Trial ,Motopetm ,Mcy 0141 For ,Multiple ,Clerosis ,Mcy Ms 001 ,